| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V44745-1mg |
≥98% | ￥1990.00 |
货期：3-5天 | - | - | - | - |
|
V44745-5mg |
≥98% | ￥4490.00 |
货期：3-5天 | - | - | - | - |
|
V44745-10mg |
≥98% | ￥7180.00 |
货期：3-5天 | - | - | - | - |
|
V44745-25mg |
≥98% | ￥10600.00 |
货期：3-5天 | - | - | - | - |
|
V44745-50mg |
≥98% | ￥17000.00 |
货期：3-5天 | - | - | - | - |
|
| 产品描述： | ADH-6 TFA is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 TFA targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53's transcriptional activity, leading to cell cycle arrest and apoptosis. ADH-6 TFA has the potential for the research of cancer diseases. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体外研究： | ADH-6 (intraperitoneal injection, 15 mg/kg, every 2 days, for a total of 12 doses) TFA causes regression of mutant p53-bearing tumors [1]. | ||||||||||||||||||||
| 体内研究： | ADH-6 (25 μM, 10 h) TFA inhibits aggregation of pR248W (indicated by dot blot assay). ADH-6 (5 μM, 6 h) TFA dissociates intracellular mutant p53 aggregates in MIA PaCa-2 cells. ADH-6 (0-10 μM, 24 or 48 h) TFA causes selective cytotoxicity in cancer cells bearing mutant p53 (MIA PaCa-2). ADH-6 (5 μM, 24 h) TFA specifically targets and reactivates aggregation-prone mutant p53 in MIA PaCa-2 cells. |
||||||||||||||||||||
| 参考文献： | 1. Palanikumar L, et al. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function. Nat Commun. 2021;12(1):3962. | ||||||||||||||||||||
| 保存条件： | 2-8°C, 干燥 | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京